Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In order to achieve a more equal balance of membership among the three classes of directors on the Board of Directors (the "Board") of Janux Therapeutics, Inc. (the "Company"), the Board determined that one of its members should be reclassified from Class III (with a term expiring at the Company's 2027 Annual Meeting of Stockholders) to Class II (with a term expiring at the Company's 2026 Annual Meeting of Stockholders).

Accordingly, on April 28, 2026, Eric Dobmeier agreed to resign from the Board and his position as a Class III director subject to, and contingent upon, his immediate reappointment as a Class II director. Effective immediately following Mr. Dobmeier's resignation, the Board reappointed him as a Class II director. The resignation and reappointment of Mr. Dobmeier was effected solely to rebalance the classes of directors on the Board and, for all other purposes, including the vesting and settlement of any outstanding equity awards and any other compensation to which Mr. Dobmeier is entitled to as a non-employee director, Mr. Dobmeier's service on the Board is deemed to have continued uninterrupted. Mr. Dobmeier will continue to serve on the Compensation Committee of the Board.